Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs

Drug Metabolism and Disposition

Volumn 35, Issue 8, 2007, Pages 1350-1364

  Prakash, Chandra ^a   Cui, Donghui ^a   Potchoiba, Michael J ^a   Butler, Todd ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CATECHOL; GLUCURONIDE; TRAXOPRODIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SELECTIVITY; FEMALE; GLUCURONIDATION; HYDROXYLATION; ISOTOPE LABELING; KIDNEY; LIVER; MALE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; UVEA; WHOLE BODY AUTORADIOGRAPHY;

ANIMALS; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FECES; FEMALE; GLUCURONIC ACID; GLUCURONIDES; INJECTIONS, INTRAVENOUS; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PIPERIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, N-METHYL-D-ASPARTATE; SEX FACTORS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; URINE;

CANIS FAMILIARIS; RATTUS;

EID: 34547225642     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016105     Document Type: Article

References (34)

1. Albin RL and Greenamyre JT (1992) Alternative excitotoxic hypothesis. Neurology 42:733-737.
2. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug Metabolites in Safety Testing. Toxicol Appl Pharmacol 182:188-196.
3. Bullock R, Kuroda Y, Teasdale GM, and McCulloch J (1992) Prevention of post-traumatic excitotoxic brain damage with NMDA antagonist drug: a new strategy for the nineties. Acta Neurochir 55:49-55.
4. Bullock MR, Merchant RE, Carmack CA, Doppenberg E, Shah AK, Wilner KD, Ko G, and Williams SA (1999) An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann N Y Acad Sci 890:51-58.
5. Chazot L (2000) CP-101606 (Pfizer Inc). Curr Opin Invest Drugs 1:370-374.
6. Chazot PL (2004) The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem 11:389-396.
7. Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL, Ducat MF, Dumont ML, Fox CB, Mena EE, et al. (1995) (1S,2S)-1-(4-Hydroxy-phenyl) -2-(4-hydroxy-4-phenyl-piperidino)-1-propanol: a potent new neuroprotectant which blocks of N-methyl-D-aspartate responses. J Med Chem 38:3138-3145.
8. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW, and Fox CB (1991) Separation of 1-adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34:3085-3090.
9. Di X, Bullock R, Watson J, Fatouros P, Chenard B, White W, and Corwin F (1997) Effect of TRXL, a novel NR2B subunit antagonist of N-methyl-D-aspartate receptor, on the volume of ischemic brain damage and cytotoxic brain edema after cerebral artery occlusion in the feline brain. Stroke 28:2241-2251.
10. Durand A, Ferrandes B, and Morselli P (1981) Pharmacokinetics of ifenprodil and its major metabolites in the male and female rats. Eur Cong Biopharm Pharmacokinet 2:136-142.
11. Furuuchi S, Naito K, Otsuka M, and Harigaya S (1985) Metabolism of denopamine, a new cardiotonic agent, in the rat and dog. Drug Metab Dispos 13:620-626.
12. Green JG and Greenamyre JT (1996) Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 48:613-634.
13. Guzikowski AP, Tamiz AP, Acosta-Burruel M, Hong-Bae S, Cai SX, Hawkinson JE, Keana JFW, Kesten SR, Shipp CT, Tran M, et al. (2000) Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (±-)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype. J Med Chem 4:984-994.
14. Johnson K, Shah A, Jaw J, Baxter J, and Prakash C (2003) Metabolism, pharmacokinetics, and excretion of a highly selective NMDA receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab Dispos 31:76-87.
15. Kamel A and Prakash C (2006) High performance liquid chromatography/ atmospheric pressure ionization /tandem mass spectrometry (HPLC/API/MS/MS) in drug metabolism and toxicology studies. Curr Drug Metab 7:837-852.
16. Larsson B and Tjalve H (1979) Studies on the mechanism of drug-binding to melanin. Biochem Pharmacol 28:1181-1187.
17. Maragos WF, Greenamyre JT, Penney JB, and Young AB (1987) Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends Neurosci 10:65-68.
18. Mattiuz EL, Ponsler GD, Barbuch RJ, Wood PG, Mullen JH, Shugert RL, Li Q, Wheeler WJ, Kuo F, Conrad PC, et al. (2003) Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metab Dispos 31 (1):88-97.
19. 14C]CP-101,606. Enantioselective crystalization of a radiochemically racemic mixture. J Labelled Comp Radiopharm 39:973-985.
20. Menniti FS, Chenard BL, Collins MA, Ducat MF, Shalaby IA, and White WF (1997) CP-101,606: a potent neuroprotectant selective for forebrain neurons. Eur J Pharmacol 331:117-126.
21. Menniti FS, Pagnozzi MJ, Butler P, Chenard BL, Jaw-Tsai S, and White WF (2000) CP-101,606, an NR2B subunit selective NMDA receptor antagonist inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology 39:1147-1155.
22. Menniti FS, Shah AK, William SA, Wilner KD, White WF, and Chenard BL (1998) CP-101,606: an NR2B-selective NMDA receptor antagonist. CNS Drug Rev 4:307-322.
23. Merchant RE, Bullock R, Carmack CA, Shah A, Wilner K, Ko G, and Williams SA (1999) A double-blind placebo-controlled trial of TRX in patients with mild or moderate traumatic brain injury. Ann N Y Acad Sci 890:42-50.
24. 3H in man and dog. Biochem J 114:8P
25. Palmer GC (2001) Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2:241-271.
26. Potchoiba MJ, Tensfeldt TG, Nocerini MR, and Silber BM (1995) A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography. J Pharmacol Exp Ther 272:953-962.
27. Potchoiba MJ, West M, and Nocerini MR (1998) Quantitative comparison of autoradioluminographic and radiometric tissue distribution studies using carbon-14 labeled xenobiotics. Drug Metab and Dispos 26:272-277.
28. Prakash C, Shaffer C, and Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369.
29. Prakash C and Soliman V (1997) Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in Long-Evans rats. Drug Metab Dispos 25:1288-1297.
30. Tanaka Y, Deguchi Y, Ishi I, and Terai T (1991a) Sex differences in excretion of zenarestat in rat. Xenobiotica 21:1119-1125.
31. Tanaka Y, Kadoh Y, Mukumoto S, and Ishikawa H (1991b) The role of age and sex hormones on the urinary excretion of zenarestat in rats. Xenobiotica 21:1273-1279.
32. Tsuchida E, Rice M, and Bullock R (1997) The neuroprotective effect of the forebrain-selective NMDA antagonist TRX upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma 14:409-417.
33. Ullberg S (1977) The technique of whole-body autoradiography cryosectioning of large specimens, in Special Issue on Whole-Body Autoradiography (O. Elvefeldt, ed), Science Tools: The LKB Instrument Journal, vol. 20, pp. 2-29. LKB, Bromma, Sweden.
34. Wood PL and Hawkinson JE (1997) N-Methyl-D-aspartate antagonists for stroke and head trauma. Expert Opin Invest Drugs 6:389-397.